Zacks Investment Research upgraded shares of Oncobiologics Inc (NYSE:ONS) from a hold rating to a buy rating in a report issued on Wednesday, May 24th. They currently have $1.50 price objective on the stock.
According to Zacks, “Oncobiologics, Inc. is a clinical-stage biopharmaceutical company which engaged in identifying, developing, manufacturing and commercializing complex biosimilar therapeutics in the disease areas of immunology and oncology. Its product pipeline consists of ONS-3010, ONS-1045, ONS-1050, ONS-1055, ONS-4010, ONS-3030, ONS-3035 and ONS-3040 which are in preclinical stage. The company employs its BioSymphony(TM) Platform to address the challenges of biosimilar development and commercialization by developing mAb biosimilars. Oncobiologics, Inc. is headquartered in Cranbury, New Jersey. “
ONS has been the subject of several other research reports. Jefferies Group LLC downgraded Oncobiologics from a buy rating to a hold rating in a report on Tuesday, March 7th. Cantor Fitzgerald restated a buy rating and issued a $15.00 price objective on shares of Oncobiologics in a research note on Thursday, April 13th.
Oncobiologics (NYSE:ONS) traded down 6.62% during mid-day trading on Wednesday, reaching $1.41. 74,762 shares of the company traded hands. Oncobiologics has a 12-month low of $1.13 and a 12-month high of $5.49. The firm’s market capitalization is $34.48 million. The company’s 50 day moving average price is $1.69 and its 200 day moving average price is $2.56.
COPYRIGHT VIOLATION WARNING: “Oncobiologics Inc (ONS) Upgraded at Zacks Investment Research” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/06/16/oncobiologics-inc-ons-upgraded-to-buy-at-zacks-investment-research-updated-updated.html.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.